Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics, a clinical-stage biotechnology company focusing on fibrotic diseases, will participate in investor events in May 2024. The events include discussions with key company executives, offering insights into the company's progress and future plans.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following May investor events.
- RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, May 14, 2024, at 1:35 p.m. Eastern Time.
- Stifel West Coast Bus Tour Members of Pliant’s senior management team will meet with investors on Thursday, May 23, 2024, as part of an invitation-only event hosted by Stifel.
- Piper Sandler Virtual Lung Investor Day Keith Cummings, M.D., Pliant’s Chief Financial Officer, and Greg Cosgrove, M.D., Pliant’s Vice President, Clinical Development, will participate in a fireside chat on Thursday, May 23, 2024, as part of an invitation-only event hosted by Piper Sandler.
Interested parties may access the live webcast of the RBC fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Phase 2b/3 trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. Pliant has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical-stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
What is Pliant Therapeutics participating in?
What is the focus of Pliant Therapeutics?
Who will participate in the fireside chat on May 14, 2024?
When will Pliant Therapeutics meet investors as part of the Stifel event?
How can interested parties access the webcast of the RBC fireside chat?
